logo

Contemporary recommendations for prostate screening incorporate the measurement of serum PSA levels into shared decision making [1]. PSA is limited by a low specificity for prostat[...]
Using the extensive data from the WHO International Agency for Research on Cancer and the United Nations Human Development Report, Greiman et al. [1] aimed to investigate how human[...]
As the year comes to an end, one cannot help but reflect on the successes of 2017. The impact factor of the BJUI has gone up to 4.439. Our infographics have introduced an entirely [...]
A number of important trends in kidney cancer diagnosis have emerged in recent decades, including the increasing detection of renal tumours in older patients with more comorbiditie[...]
Guidelines now recommend performing multiparametric MRI (mpMRI) and targeted prostate biopsies in men with a history of prior negative biopsy and continued concern for significant [...]
Stone disease is a highly prevalent condition that unites all countries around the world, although surgical management will depend on many factors including availability of differe[...]
Huddart et al. [1] report the results of a phase III clinical trial (SPARE) evaluating the feasibility of randomising participants with cT2/T3 muscle-invasive bladder cancer (MIBC)[...]
The article by Rizvi et al. [1] makes a great read. The authors deserve credit for their work and the data presented. A few points merit mention to summarise and put the article in[...]
In science, reports showing data deviating from what is expected are called anomalous observations. Metabolic syndrome (MetS) is a promoter of cancer at almost all sites [1]; howev[...]
The publication in this issue of the BJUI by Veeratterapillay et al. [1] of a UK multicentre study in a community setting marks a watershed in the availability and quality of minim[...]